Elation, pride, and a slew of questions: Clinical trial participants reflect on their own complicated reactions to Aduhelm approval

For the roughly 3,500 people who volunteered as clinical trial participants for the Alzheimer’s therapy Aduhelm, Monday’s divisive approval spurred a complicated brew of emotions.

There was elation, yes — that the endorsement of the therapy by the Food and Drug Administration was a validation that maybe it really had been working for them, that it was letting them take the dog for a walk, or embrace new projects, or have a simple conversation with their spouse for more years than they could have otherwise.

Read the rest…